AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26494856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose FOLFIRI plus bevacizumab (overall population)
Number of subjects: 86
Study 24494468 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive group (RG) with low range of ITBVI (600‐800 ml/m2)
Number of subjects: 22
Study 24494468 — intervention group
Group type: COMPARATOR
Intervention: Liberal group (LG) with normal ITBVI (800‐1000 ml/m2)
Number of subjects: 22
Study 21272714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal padded aluminum splint
Number of subjects: 64
Study 21272714 — intervention group
Group type: COMPARATOR
Intervention: Stack splint (control)
Number of subjects: 64
Study 21272714 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made thermoplastic thimble splint
Number of subjects: 64
Study 21272714 — intervention group
Group type: EXPERIMENTAL
Intervention: All splint types
Number of subjects: 64
Study 20209995 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution
Number of subjects: 0
Study 20209995 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbalanced crystalloid solution
Number of subjects: 0
Study 16377095 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter AR CAG repeat polymorphisms (<17) in violent criminals
Number of subjects: 254
Study 16377095 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 254
Study 14742364 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive great auricular nerve block (GAN-block) with 0.25% bupivacaine with 1:200,000 epinephrine
Number of subjects: 40
Study 14742364 — intervention group
Group type: COMPARATOR
Intervention: Preemptive great auricular nerve block with normal saline (sham block)
Number of subjects: 40
Study 11730815 — intervention group
Group type: COMPARATOR
Intervention: CEE+MPA
Number of subjects: 105
Study 11730815 — intervention group
Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 105
Study 11730815 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine induced dilatation
Number of subjects: 105
Study 9229214 — intervention group
Group type: COMPARATOR
Intervention: Diet records
Number of subjects: 101
Study 9229214 — intervention group
Group type: COMPARATOR
Intervention: Food frequency questionnaires
Number of subjects: 101
Study 9229214 — intervention group
Group type: COMPARATOR
Intervention: Modules (brief food frequency questionnaires)
Number of subjects: 101
Study 9229214 — intervention group
Group type: COMPARATOR
Intervention: Modules
Number of subjects: 101
Study 9229214 — intervention group
Group type: COMPARATOR
Intervention: All methods
Number of subjects: 101
Study 7525694 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (recombinant interferon-alpha 2a)
Number of subjects: 55
Study 3593452 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (100 mg)
Number of subjects: 30
Study 3593452 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide (200 mg)
Number of subjects: 30
Study 29508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoplant tablets and Venoplant gel
Number of subjects: 43
Study 29508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Only Venoplant tablets
Number of subjects: 43
Study 29508020 — intervention group
Group type: COMPARATOR
Intervention: Not treated with Venoplant
Number of subjects: 43
Study 27163717 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ppm F plus 1% TMP (500TMP)
Number of subjects: 600
Study 27163717 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ppm F plus 0.25% CaGP (500CaGP)
Number of subjects: 600
Study 27163717 — intervention group
Group type: COMPARATOR
Intervention: 1100ppm F (1100F)
Number of subjects: 600
Study 24924800 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (250 mg)
Number of subjects: 47
Study 24924800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 22884641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 175
Study 22884641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 20211002 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg once-daily
Number of subjects: 416
Study 20211002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 18596108 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1‐(7‐36) amide
Number of subjects: 48
Study 18596108 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 48
Study 18596108 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐NMMA
Number of subjects: 48
Study 18596108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 48
Study 15667544 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% albumin
Number of subjects: 58
Study 15667544 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 58
Study 15667544 — intervention group
Group type: COMPARATOR
Intervention: Maintenance only (control)
Number of subjects: 58
Study 11568777 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg daily
Number of subjects: 95
Study 11568777 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (ccHRT)
Number of subjects: 95
Study 11568777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 9760819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 50
Study 9760819 — intervention group
Group type: COMPARATOR
Intervention: Nondialyzed patients
Number of subjects: 50
Study 9760819 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (HD and nondialyzed)
Number of subjects: 50
Study 9760819 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 50
Study 8311206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide uptake during spontaneous ventilation
Number of subjects: 40
Study 8311206 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide uptake during controlled ventilation
Number of subjects: 40
Study 2449062 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 94
Study 2449062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30295296 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dinner moderate-intensity exercise (20 minutes on a treadmill, heart rate reserve of 40%)
Number of subjects: 29
Study 30295296 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercise condition)
Number of subjects: 29
Study 27811949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraileal protein infusion (15 g over 60 min)
Number of subjects: 14
Study 27811949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraileal protein infusion
Number of subjects: 14
Study 27811949 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal protein infusion
Number of subjects: 14
Study 27811949 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study 27811949 — intervention group
Group type: COMPARATOR
Intervention: Jejunal protein infusion
Number of subjects: 14
Study 23879783 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical education program
Number of subjects: 396
Study 23879783 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical education program
Number of subjects: 396
Study 21824950 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone tablets, 200 mg daily
Number of subjects: 248
Study 21824950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 19909027 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based educational intervention on rational prescribing
Number of subjects: 112
Study 19909027 — intervention group
Group type: COMPARATOR
Intervention: Traditional CME program on rational prescribing
Number of subjects: 112
Study 17129981 — intervention group
Group type: EXPERIMENTAL
Intervention: Average LDL particle size below the median (261.2 Angstrom)
Number of subjects: 176
Study 17129981 — intervention group
Group type: COMPARATOR
Intervention: LDL particle size above the median (261.2 Angstrom)
Number of subjects: 176
Study 15612958 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrathoracic expiratory resistance (EER; 0.89 kPa/L s at a flow of 0.5 L/s)
Number of subjects: 31
Study 15612958 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 31
Study 15612958 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 31
Study 11689035 — intervention group
Group type: EXPERIMENTAL
Intervention: Configural and featural cues
Number of subjects: 0
Study 11689035 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure and experimenter feedback
Number of subjects: 0
Study 11689035 — intervention group
Group type: COMPARATOR
Intervention: Superfluous paraphernalia (hat)
Number of subjects: 0
Study 9550501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering therapy with statins
Number of subjects: 1351
Study 9550501 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy
Number of subjects: 1351
Study 7942651 — intervention group
Group type: EXPERIMENTAL
Intervention: Arch wire adjustment
Number of subjects: 22
Study 7942651 — intervention group
Group type: COMPARATOR
Intervention: Placebo adjustment
Number of subjects: 22
Study 3191894 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 95
Study 31236643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (900 mg CF)
Number of subjects: 11
Study 31236643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 mg CF)
Number of subjects: 11
Study 27688295 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and request for consent for biospecimen and data sharing by the patient's physician
Number of subjects: 140
Study 27688295 — intervention group
Group type: COMPARATOR
Intervention: Information and request for consent for biospecimen and data sharing by a research assistant
Number of subjects: 140
Study 26556082 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment group + visual spatial attention (optokinetic stimulation and right half‐field eye patching)
Number of subjects: 9
Study 26556082 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (only conventional rehabilitation training)
Number of subjects: 9
Study 24236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Female threat condition
Number of subjects: 161
Study 24236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Male threat condition
Number of subjects: 161
Study 24236380 — intervention group
Group type: COMPARATOR
Intervention: No threat condition
Number of subjects: 161
Study 24236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic anxiety
Number of subjects: 161
Study 21218282 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance in obtaining dental care
Number of subjects: 593
Study 21218282 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable housing, more than a high school education, and received help in getting dental care
Number of subjects: 593
Study 21218282 — intervention group
Group type: COMPARATOR
Intervention: Black respondents
Number of subjects: 593
Study 21218282 — intervention group
Group type: COMPARATOR
Intervention: Availability of dental services for low-income HIV-positive persons
Number of subjects: 593
Study 19221130 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including a general medical assessment and specific fall risk evaluation tool applied by a multidisciplinary fall prevention team
Number of subjects: 518
Study 19221130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 518
Study 22472671 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 80
Study 22472671 — intervention group
Group type: COMPARATOR
Intervention: Control (no abdominal massage)
Number of subjects: 80
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: AF patients
Number of subjects: 124
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: AF patients with hypertension
Number of subjects: 124
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: AF patients with left ventricular hypertrophy
Number of subjects: 124
Study 15673377 — intervention group
Group type: COMPARATOR
Intervention: Control patients with hypertension
Number of subjects: 124
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AF patients
Number of subjects: 124
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 124
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 124
Study 15673377 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AF
Number of subjects: 124
Study 12860586 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat strategy by H pylori serology
Number of subjects: 270
Study 12860586 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy with Helicobacter pylori testing
Number of subjects: 270
Study 12860586 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat strategy
Number of subjects: 270
Study 12860586 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy group
Number of subjects: 270
Study 12860586 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat group
Number of subjects: 270
Study 10215812 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 100
Study 10215812 — intervention group
Group type: COMPARATOR
Intervention: Side-to-side anastomosis
Number of subjects: 100
Study 8545170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced bronchoconstriction
Number of subjects: 14
Study 8545170 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchoconstriction
Number of subjects: 14
Study 8545170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced bronchoconstriction in older age group (11-12 years, n = 5)
Number of subjects: 14
Study 8545170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced bronchoconstriction in younger age group (7-10 years, n = 9)
Number of subjects: 14
Study 8545170 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchoconstriction in older age group (11-12 years, n = 5)
Number of subjects: 14
Study 8545170 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchoconstriction in younger age group (7-10 years, n = 9)
Number of subjects: 14
Study 2548222 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 14
Study 2548222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1269192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol (1 mg/kg)
Number of subjects: 6
Study 1269192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acebutolol (3 X 100 mg)
Number of subjects: 6
Study 1269192 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal clearance of acebutolol (after intravenous dosing)
Number of subjects: 6
Study 30832766 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle fatigue induced by physical exertion
Number of subjects: 0
Study 30832766 — intervention group
Group type: EXPERIMENTAL
Intervention: Altering motor cortex function
Number of subjects: 0
Study 27373976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg body weight of gadobenate dimeglumine (MultiHance)
Number of subjects: 65
Study 27373976 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg body weight of gadoterate meglumine (Dotarem)
Number of subjects: 65
Study 26304663 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus medical therapy
Number of subjects: 2136
Study 26304663 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with surgical ventricular reconstruction
Number of subjects: 2136
Study 26304663 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2136
Study 23488859 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (12-week duration)
Number of subjects: 93
Study 23488859 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 21515998 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Learning program for operating room nursing
Number of subjects: 74
Study 21515998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e-Learning program)
Number of subjects: 74
Study 18813941 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate electrolyte solution (CHO)
Number of subjects: 12
Study 18813941 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (PLA)
Number of subjects: 12
Study 18813941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CHO and PLA
Number of subjects: 12
Study 16542576 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg, q12 h) before catheterization
Number of subjects: 966
Study 16542576 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH 25 mg intravenously before coronary angiography, additional 65 mg if PCI performed)
Number of subjects: 966
Study 16542576 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 966
Study 16542576 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 966
Study 14499421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine, 2 mg
Number of subjects: 7
Study 14499421 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine, 2 mg
Number of subjects: 7
Study 10709052 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-tex graft
Number of subjects: 240
Study 10709052 — intervention group
Group type: COMPARATOR
Intervention: Hemashield graft
Number of subjects: 240
Study 10709052 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 65 years
Number of subjects: 240
Study 10709052 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts with diameter less than 7 mm
Number of subjects: 240
Study 9314644 — intervention group
Group type: EXPERIMENTAL
Intervention: 30/70 IA (insulin aspart)
Number of subjects: 24
Study 9314644 — intervention group
Group type: COMPARATOR
Intervention: 30/70 HI (human insulin)
Number of subjects: 24
Study 1549026 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid glucose (G)
Number of subjects: 5
Study 1549026 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined hot cereal (R)
Number of subjects: 5
Study 1549026 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined hot cereal with water-soluble fiber (R/F)
Number of subjects: 5
Study 1549026 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bar (O)
Number of subjects: 5
Study 1549026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 5
Study 3900856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbamazepine
Number of subjects: 0
Study 3900856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 0
Study 3900856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29991121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus mattress overlay use
Number of subjects: 38
Study 29991121 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation only
Number of subjects: 38
Study 28830541 — intervention group
Group type: EXPERIMENTAL
Intervention: Platycodon grandiflorum granules
Number of subjects: 120
Study 28830541 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 120
Study 26303347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored social cognitive intervention (SC) using a '5 As'-based personal action planning tool
Number of subjects: 452
Study 26303347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of both ENV and SC approaches (COMBO)
Number of subjects: 452
Study 26303347 — intervention group
Group type: COMPARATOR
Intervention: Matched contact nutrition control (CON)
Number of subjects: 452
Study 26303347 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased environmental accessibility to PA resources via the provision of a free voucher to a fitness facility (ENV)
Number of subjects: 452
Study 23247712 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Kaatsu training (CUFF) with three sets of 15 repetitions of unilateral biceps and triceps exercises, three times per week for 8 weeks.
Number of subjects: 40
Study 23247712 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (CON) group wearing the cuff on one arm for a comparable amount of time.
Number of subjects: 40
Study 23247712 — intervention group
Group type: EXPERIMENTAL
Intervention: EX group compliance
Number of subjects: 40
Study 23247712 — intervention group
Group type: COMPARATOR
Intervention: CON group compliance
Number of subjects: 40
Study 23247712 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived exertion and sensations during workouts using visual analog scales.
Number of subjects: 40
Study 21308882 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 291
Study 21308882 — intervention group
Group type: COMPARATOR
Intervention: IPT
Number of subjects: 291
Study 18085337 — intervention group
Group type: EXPERIMENTAL
Intervention: Spasm-controlled group
Number of subjects: 0
Study 18085337 — intervention group
Group type: COMPARATOR
Intervention: Fissure apex group
Number of subjects: 0
Study 16533239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% miconazole nitrate paste
Number of subjects: 40
Study 16533239 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated paste
Number of subjects: 40
Study 14743985 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES 3 times per week
Number of subjects: 27
Study 14743985 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES 2 times per week
Number of subjects: 27
Study 14743985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 27
Study 11235728 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional UF during bypass + venovenous MUF after bypass
Number of subjects: 40
Study 11235728 — intervention group
Group type: COMPARATOR
Intervention: No UF
Number of subjects: 40
Study 9774816 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient neurological care
Number of subjects: 954